Moderna announced this week that they are working on a two-in-one vaccine that would combine their covid vaccine with a flu shot currently under development. The new shot, called mRNA-1073, would hopefully increase convenience for individuals who plan on receiving a booster shot. The company hopes that the vaccine will be updated and administered yearly, much as the flu vaccine is today. Clinical testing is expected to begin in the next 6 to 12 months. Following the news, the cost of Moderna’s shares increased by more than 5%. The company also has plans to produce a pediatric vaccine that aims to protect against respiratory syncytial virus and human metapneumovirus. Read more about the vaccine here and more about the market response here.